^
    3ms
    Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Deciphera Pharmaceuticals LLC
    New P1/2 trial
    |
    DCC-3084
    1year
    DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models (AACR 2023)
    The Switch Control inhibitor DCC-3084 broadly inhibits Class I, II and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers leading to tumor regression in preclinical models. The overall preclinical profile of DCC-3084 supports IND-enabling activities towards clinical development in a key area of unmet medical need in RAS and RAF mutant cancers.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RAS mutation • BRAF fusion • KRAS Q61K
    |
    DCC-3084